Powered by

Home Hindi

Can Remdesivir prevent COVID-19?

While there in a rapid increase in the number of COVID-19 cases, Scientists found hope in U.S. firm’s antiviral drug Remdesivir.

By Radhika12
New Update
remedesivir considering-removal from treatment of covid-19 plasma therapy

Scientists have found a ray of hope in U.S. biopharmaceutical firm’s antiviral drug Remdesivir. There is a rapid increase in the number of COVID-19 cases in India and around the world. Initially it was used for the deadly Ebola virus five years ago. But has now shown promise by modestly speeding recovery from COVID-19, experts said.

A study was conducted by the tracker maintained by the Milken Institute, an independent economic think tank in the US. It said, more than 130 drugs are under experimentation to treat COVID-19. Some may have the potential to stop the virus while others may help calm overactive immune responses that damage organs.

ALSO READ: A Failed Government Led To “Hard Time” For Delhi?

"Right now, there is only one effective approach which is to repurpose already approved drugs for other diseases if they can be used for COVID-19. One example is remdesivir," Ram Vishwakarma, Director of the Indian Institute of Integrative Medicine, CSIR, Jammu, told PTI.

Remdesivir is helping people recover faster, and is lowering the death rate among critically ill patients. It can be life-saving, we do not have time to develop new drugs and new drug development takes five-10 years. So we are using existing drugs and conducting clinical trials to find if any of them are effective, Vishwakarma said.

Molecules available for treating HIV or other viral infections can be quickly checked against the novel coronavirus, he explained. If found effective, they can be used against COVID-19 with the appropriate approval from drug control bodies.

When drug company Gilead Sciences sought to begin clinical trials for remdesivir, it immediately got approval from the US FDA.

ALSO READ: Delhi Failing In COVID-19 Tests?

INDIA in talks to manufacture Remdesivir

Dr. Reddy’s Laboratories on Saturday said it has signed a non-exclusive licensing agreement with Gilead Sciences. The agreement will be to register manufacture and sell the U.S. biopharmaceutical firm’s antiviral drug remdesivir. The drug has emerged as a potential treatment for COVID-19.

Biocon firm Syngene and Zydus Cadila Healthcare have also entered into similar agreements with Gilead. They get to manufacture the product for distribution in 127 countries.

They join Hetero Labs, Jubilant Lifesciences, and Mylan, who had signed the agreement last month with Gilead.

An investigational antiviral therapy, remdesivir has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (USFDA) to treat COVID-19. Phase 3 clinical studies to evaluate the safety and efficacy of the drug are underway. In India, the Union Health Ministry had recently cleared remdesivir for the treatment of COVID-19 patients under emergency use.

Other drugs are also under trial

Some drugs developed to treat HIV, such as lopinavir and ritonavir, are also being tested to cure COVID-19, Vishwakarma said.

  • A study published in Lancet this month said a treatment involving a combination of the drugs interferon beta-1b, plus the antiviral combination lopinavir-ritonavir and ribavirin, is better at reducing the viral load or quantity of the virus than lopinavir-ritonavir alone.
  • Another study published last month in the journal Science noted the effectiveness of two small molecule drug candidates named 11a and 11b which could block the SARS-CoV-2 M protease enzyme, which the virus uses to make copies of itself. The molecules could stop the virus from replicating in monkey cells and have been found safe for administration in rats and beagles, with the study concluding that both the drugs warrant further studies.
  • Another team from the University of Washington in the US found recently that a combination of antibodies, including those from a patient who had recovered from the 2002-03 SARS pandemic virus infection, can effectively block the novel coronavirus. One of these molecules, named S309, showed particularly strong neutralizing activity against SARS-CoV-2, they said, adding that it can act in combination with another, a less potent antibody that targets a different site on the virus

Written By Radhika Bansal, She is doing her Masters in Journalism and Mass Communication from Amity University, Noida. She is interested in covering political and humanitarian issues.

You can connect with Ground Report on FacebookTwitter and Whatsapp, and mail us at [email protected] to send us your suggestions and writeups.